Shore N - Search Results

1

Long-term efficacy and tolerability of once-yearly histrelin acetate subcutaneous implant in patients with advanced prostate cancer.

Shore N, Cookson MS, Gittelman MC. Shore N, et al. BJU Int. 2012 Jan;109(2):226-32. doi: 10.1111/j.1464-410X.2011.10370.x. Epub 2011 Aug 18. BJU Int. 2012. PMID: 21851539 Clinical Trial.

2

The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.

Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P, Jensen JK, Olesen TK, Schröder FH. Klotz L, et al. BJU Int. 2008 Dec;102(11):1531-8. doi: 10.1111/j.1464-410X.2008.08183.x. BJU Int. 2008. PMID: 19035858 Clinical Trial.

3

Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study.

Schröder FH, Tombal B, Miller K, Boccon-Gibod L, Shore ND, Crawford ED, Moul J, Olesen TK, Persson BE. Schröder FH, et al. BJU Int. 2010 Jul;106(2):182-7. doi: 10.1111/j.1464-410X.2009.08981.x. Epub 2009 Nov 13. BJU Int. 2010. PMID: 19912212 Clinical Trial.

4

Testosterone in prostate cancer: the Bethesda consensus.

Djavan B, Eastham J, Gomella L, Tombal B, Taneja S, Dianat SS, Kazzazi A, Shore N, Abrahamsson PA, Cheetham P, Moul J, Lepor H, Crawford ED. Djavan B, et al. Among authors: shore n. BJU Int. 2012 Aug;110(3):344-52. doi: 10.1111/j.1464-410X.2011.10719.x. Epub 2011 Nov 30. BJU Int. 2012. PMID: 22129242 Review.

5

New developments in castrate-resistant prostate cancer.

Shore N, Mason M, de Reijke TM. Shore N, et al. BJU Int. 2012 Jun;109 Suppl 6:22-32. doi: 10.1111/j.1464-410X.2012.11217.x. BJU Int. 2012. PMID: 22672122 Review.

6

New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists.

Shore ND, Abrahamsson PA, Anderson J, Crawford ED, Lange P. Shore ND, et al. Prostate Cancer Prostatic Dis. 2013 Mar;16(1):7-15. doi: 10.1038/pcan.2012.25. Epub 2012 Jul 3. Prostate Cancer Prostatic Dis. 2013. PMID: 22751146 Review.

7

Highlights in advanced prostate cancer from the 2012 American Urological Association Annual Meeting and the 2012 American Society of Clinical Oncology Annual Meeting.

Shore ND. Shore ND. Clin Adv Hematol Oncol. 2012 Aug;10(8 Suppl 12):1-24. Clin Adv Hematol Oncol. 2012. PMID: 23072827 No abstract available.

8

Comparison of tolerability and adverse events following treatment with two GnRH agonists in patients with advanced prostate cancer.

Shore ND, Sieber P, Schimke L, Perzin A, Olsen S. Shore ND, et al. Urol Nurs. 2013 Sep-Oct;33(5):236-44, 248. Urol Nurs. 2013. PMID: 24354113 Clinical Trial.

9

Advances in the understanding of cancer immunotherapy.

Shore ND. Shore ND. BJU Int. 2015 Sep;116(3):321-9. doi: 10.1111/bju.12692. Epub 2015 May 18. BJU Int. 2015. PMID: 24612369 Review.

10

Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302).

Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, Shore ND, de Souza P, Fizazi K, Mulders PF, Mainwaring P, Hainsworth JD, Beer TM, North S, Fradet Y, Van Poppel H, Carles J, Flaig TW, Efstathiou E, Yu EY, Higano CS, Taplin ME, Griffin TW, Todd MB, Yu MK, Park YC, Kheoh T, Small EJ, Scher HI, Molina A, Ryan CJ, Saad F. Rathkopf DE, et al. Eur Urol. 2014 Nov;66(5):815-25. doi: 10.1016/j.eururo.2014.02.056. Epub 2014 Mar 6. Eur Urol. 2014. PMID: 24647231 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

514 results

Search Page